07:00 , Apr 17, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Fas receptor (CD95) In vitro and mouse studies suggest blocking CD95 signaling could help treat breast cancer. CD95 signaling can promote apoptosis in...
08:00 , Jan 14, 2013 |  BioCentury  |  Emerging Company Profile

Oncology Venture: Enrichment tool

Oncology Venture ApS has an exclusive license to a computational method to predict patient response to cancer therapies that could provide an efficient and cost-effective way to repurpose compounds that have failed in prior cancer...
08:00 , Nov 19, 2012 |  BC Week In Review  |  Company News

Oncology Venture, Topotarget deal

Newco Oncology Venture debuted and acquired exclusive, worldwide rights from Topotarget to APO010 , a recombinant fusion protein drug consisting of three human Fas ligands (TNF superfamily, member 6; FASL ). In 2Q13, Oncology Venture...
02:28 , Nov 14, 2012 |  BC Extra  |  Company News

Oncology Venture gains rights to Topotarget's APO010

Newco Oncology Venture ApS (Copenhagen, Denmark) debuted on Tuesday and acquired exclusive, worldwide rights from Topotarget A/S (CSE:TOPO) to APO010, a recombinant fusion protein drug consisting of three human Fas ligands (TNF superfamily, member 6;...
08:00 , Dec 17, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Obesity Fas receptor (CD95) A study in mice and in human cell culture suggests that antagonizing CD95 in adipocytes could help treat obesity. Adipocytes...
07:00 , Oct 29, 2009 |  BC Innovations  |  Targets & Mechanisms

New autoimmunity targets

Apoptotic cell clearance has been posited as a potential strategy to help prevent autoimmunity, but so far it has not been clear how to modulate the process. Now, two research groups have described actual targets...
07:00 , Apr 16, 2007 |  BC Week In Review  |  Company News

Apoxis, Topotarget deal

TOPO will acquire Apoxis for E14.5 million ($19.4 million) in stock. Apoxis’ shareholders will provide Apoxis with a E4 million ($5.3 million) convertible loan prior to the deal’s close and will be eligible for more...